Payment overview · 2025
General Payments
$257.95
24 reported records · 7 companies
Healthcare provider profile · identity verified
Kellie Planck
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GAS CITY, IN · NPI 1144680679
Verified facts
What the public records show
CMS Open Payments records show Kellie Planck received $257.95 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 57.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $147.47 | 57.2% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.20 | 9.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.14 | 8.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.75 | 8.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.22 | 6.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.65 | 5.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.52 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $257.95 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.57 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.90 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.90 | 9 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.65 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 147 |
| Omeprazole | Omeprazole | 554 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 94 |
| Lisinopril | Lisinopril | 368 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 325 | 60 |
| Losartan Potassium | Losartan Potassium | 322 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 54 |
| Meloxicam | Meloxicam | 239 | 49 |
| Metformin Hcl | Metformin Hcl | 227 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 223 | 39 |
| Gabapentin | Gabapentin | 210 | 42 |
| Simvastatin | Simvastatin | 184 | 32 |
| Glimepiride | Glimepiride | 143 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 30 |
| Furosemide | Furosemide | 141 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 27 |
| Famotidine | Famotidine | 126 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 28 |
| Fenofibrate | Fenofibrate | 114 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 21 |
| Trazodone Hcl | Trazodone Hcl | 111 | 25 |
| Ozempic | Semaglutide | 107 | 16 |
| Alendronate Sodium | Alendronate Sodium | 103 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 22 |
| Montelukast Sodium | Montelukast Sodium | 96 | 18 |
| Tramadol Hcl | Tramadol Hcl | 96 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 87 | 16 |
| Jardiance | Empagliflozin | 85 | suppressed |
| Potassium Chloride | Potassium Chloride | 81 | 17 |
| Metformin Hcl Er | Metformin Hcl | 75 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 18 |
| Eliquis | Apixaban | 73 | 14 |
| Sertraline Hcl | Sertraline Hcl | 73 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 17 |
| Buspirone Hcl | Buspirone Hcl | 65 | 16 |
| Bupropion Xl | Bupropion Hcl | 62 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 12 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Carvedilol | Carvedilol | 59 | 19 |
| Alprazolam | Alprazolam | 52 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 52 | suppressed |
| Linzess | Linaclotide | 52 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 50 | 11 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 47 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 13 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Valsartan | Valsartan | 36 | 12 |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 11 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 26 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Nystatin | Nystatin | 26 | 15 |
| Prednisone | Prednisone | 26 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estarylla | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.95 · 24 records | ABBVIE INC. | FANAPT, Kerendia, Korlym, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error